BioCryst Pharmaceuticals CEO and leadership

Jon P. Stonehouse, a pharmaceutical executive for more than 20 years, has strong commercialization, financial transaction, business development and management expertise. He most recently served as Senior Vice President of Corporate Development at Merck KGaA with responsibility for global licensing and business development, corporate mergers and acquisitions, corporate strategic planning and alliance management. Among his accomplishments, he was responsible for leading the effort to develop a strategy for Merck that significantly changed the company. This culminated with the acquisition of Serono, S.A., the largest biotechnology company in Europe at the time of the agreement.

Dr. William Sheridan joined BioCryst in July 2008. Dr. Sheridan is a seasoned biotechnology professional. During a 15-year tenure at Amgen, Dr. Sheridan organized and led the company's U.S. Medical Affairs function, making significant contributions to the successful launch of many compounds, including Aranesp®, Enbrel®, Kineret®, Neulasta® and Sensipar®, and led several product development teams. At Amgen, Dr. Sheridan held titles at the Vice President level in North American Medical Affairs, International Medical Affairs, Global Health Economics and Outcomes Research, U.S. Medical Affairs, and Product Development. He played an integral role in building Amgen's domestic and international medical affairs functions and in forming the health economics and outcomes unit. Dr. Sheridan earned his MB BS degree (M.D. equivalent) at the University of Melbourne in Victoria, Australia. Dr. Sheridan is a board-certified fellow of the Royal Australasian College of Physicians (FRACP), with a sub-specialty in medical oncology, and a Fellow of the American College of Physicians.

Charles Gayer is a Chief Commercial Officer at BIOCRYST PHARMACEUTICALS INC and is based in Durham, North Carolina. He has worked as Product Manager/Senior Product Manager at GSK; Senior Director, Immunology Marketing at Grifols; and Senior Director, International Marketing at Grifols. Charles studied at Fuqua School of Business between 1999 and 2001 and Princeton University between 1989 and 1993.

Successful Senior Finance Executive with ~20 years of global experience in driving strategy and growth, building strong global Finance teams, building customer relationships, overseeing significant return on investment to shareholders and serving as a key adviser and member of company management.

Areas of expertise: Chief Financial Officer / Private Equity / Risk Management / Corporate Governance / Investment Decisions / Working Capital Management / Turnaround / Productivity / M&A / Integration / Financial Planning & Analysis / Manufacturing / IT and Software / Healthcare Industries / Clinical Research / Financial Services / Pharmaceuticals / Professional Services / Lean Six Sigma

Jon P. Stonehouse, a pharmaceutical executive for more than 20 years, has strong commercialization, financial transaction, business development and management expertise. He most recently served as Senior Vice President of Corporate Development at Merck KGaA with responsibility for global licensing and business development, corporate mergers and acquisitions, corporate strategic planning and alliance management. Among his accomplishments, he was responsible for leading the effort to develop a strategy for Merck that significantly changed the company. This culminated with the acquisition of Serono, S.A., the largest biotechnology company in Europe at the time of the agreement.